Prosecution Insights
Last updated: November 18, 2026

Emory University

Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering

33 pending office actions • 24 art units • 33 examiners • 0 of 33 (0%) have an AI response strategy ready • 28 patents granted in the last 365 days

Analysis

Emory University has 32 pending office actions in Biotechnology & Pharmaceuticals. Those matters involve 32 distinct examiners and 24 distinct art units. The examiner count matches the pending-action count, while the art-unit count is lower, indicating that some technology units receive matters from more than one examiner.

KUO, JONATHAN T is the busiest examiner, with 1 pending matter. No examiner carries multiple listed matters, so the principal management issue is breadth across individual examiner assignments rather than concentration with one examiner.

The 24 art units create a broader organizational pattern than a single-unit portfolio but still provide potential points for technology-based coordination. Counsel can use art-unit grouping to identify recurring examination themes, while preserving examiner-specific response analysis for each action.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

33
Total Pending OAs
24
Non-Final OAs
9
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

4
Overdue
1
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (4)Due ≤ 7 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

18
Hard (55%)
12
Medium (36%)
3
Easy (9%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other3 (9%)
§103 only7 (21%)
§102 only1 (3%)
§112 only3 (9%)
Double-patenting + other4 (12%)
Multi-statute (no §101)15 (45%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

24
Life Sciences
73% of docket
1
Information Tech
3% of docket
1
Communications
3% of docket
0
Semiconductors
0% of docket
7
Mechanical / Eng
21% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

330 h
Manual time on pending OAs
66 h
Time saved (low, 20%)
115 h
Time saved (mid, 35%)
2.9 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KUO, JONATHAN T 1 72.3% +28.8%
TOTH, KAREN E 1 46.4% +25.9%
OKEKE, IZUNNA 1 81.7% +15.2%
HUYNH, VAN D 1 87.2% +13.0%
RUSSELL, SYDNEY REYES 1 48.7% +51.3%
LUKJAN, SEBASTIAN X 1 76.4% +40.1%
BARRON, SEAN C 1 52.6% +30.9%
STOCKTON, LAURA LYNNE 1 75.3% +33.6%
BANERJEE, KOYELI 1 33.3% +0.0%
GRABER, JAMES J 1 46.5% +57.6%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18853930 DEVICES, SYSTEMS AND METHODS FOR SECURING COMMUNICATION INTEGRITY OKEKE, IZUNNA —

Hard Cases (18)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18000865 DIRECT IN VIVO REPROGRAMMING USING TRANSCRIPTION FACTOR ETV2 GENE FOR ENDOTHELIAL CELL AND VESSEL FORMATION KIM, TAEYOON 49d overdue
17435594 Botanical Extracts and Compounds from Castanea Plants and Methods of Use ISMAIL, REHANA 30d overdue
18558026 CELL POTENCY ASSAYS, PLATFORMS, AND METHODS OF USE ARMATO JR, DENNIS IGNATIUS 6d
18993727 RECORDING AND RECOVERY OF SIGNALS DURING STIMULATION KUO, JONATHAN T —
18869731 HAPTICALLY-ENABLED FOOT ANKLE ORTHOSIS FOR POST-INJURY PLANAR PRESSURE MONITORING AND MODULATION TOTH, KAREN E —
18901408 MEDICAL ANALYSIS USING SPATIOTEMPORAL ANALYSIS AND TRANSFORMER-BASED MODELS HUYNH, VAN D —
18847528 PNEUMATIC COMPRESSION VEST DEVICE, METHOD, AND SYSTEM FOR TRANSTHORACIC MANIPULATION FOR OXYGENATION RUSSELL, SYDNEY REYES —
18819710 SYSTEM AND METHODS FOR AUTOMATED DEEP BRAIN STIMULATION PARAMETER SELECTION VIA META-ACTIVE LEARNING OF EVOKED POTENTIALS LUKJAN, SEBASTIAN X —

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18993727 RECORDING AND RECOVERY OF SIGNALS DURING STIMULATION KUO, JONATHAN T —
18869731 HAPTICALLY-ENABLED FOOT ANKLE ORTHOSIS FOR POST-INJURY PLANAR PRESSURE MONITORING AND MODULATION TOTH, KAREN E —
18853930 DEVICES, SYSTEMS AND METHODS FOR SECURING COMMUNICATION INTEGRITY OKEKE, IZUNNA —
18901408 MEDICAL ANALYSIS USING SPATIOTEMPORAL ANALYSIS AND TRANSFORMER-BASED MODELS HUYNH, VAN D —
18847528 PNEUMATIC COMPRESSION VEST DEVICE, METHOD, AND SYSTEM FOR TRANSTHORACIC MANIPULATION FOR OXYGENATION RUSSELL, SYDNEY REYES —
18819710 SYSTEM AND METHODS FOR AUTOMATED DEEP BRAIN STIMULATION PARAMETER SELECTION VIA META-ACTIVE LEARNING OF EVOKED POTENTIALS LUKJAN, SEBASTIAN X —
18730610 Phosphate Membrane Nanodiscs Conjugated to Therapeutic Agents and Medical Uses Thereof BARRON, SEAN C —
18756360 Nucleoside Prodrugs and Uses Related Thereto STOCKTON, LAURA LYNNE —

Top Art Units

Art UnitApps
1631 3
1693 3
3792 2
3791 2
1626 2
1691 2
1625 2
2497 1
2665 1
3785 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18993727 RECORDING AND RECOVERY OF SIGNALS DURING STIMULATION KUO, JONATHAN T 3792 §102§103§112 Non-Final OA — Pending Jan 13, 2025
18869731 HAPTICALLY-ENABLED FOOT ANKLE ORTHOSIS FOR POST-INJURY PLANAR PRESSURE MONITORING AND MODULATION TOTH, KAREN E 3791 §102§103§112 Non-Final OA — Pending Nov 26, 2024
18853930 DEVICES, SYSTEMS AND METHODS FOR SECURING COMMUNICATION INTEGRITY OKEKE, IZUNNA 2497 §103 Non-Final OA — Pending Oct 03, 2024
18901408 MEDICAL ANALYSIS USING SPATIOTEMPORAL ANALYSIS AND TRANSFORMER-BASED MODELS HUYNH, VAN D 2665 §102§103 Non-Final OA — Pending Sep 30, 2024
18847528 PNEUMATIC COMPRESSION VEST DEVICE, METHOD, AND SYSTEM FOR TRANSTHORACIC MANIPULATION FOR OXYGENATION RUSSELL, SYDNEY REYES 3785 §102§103§112 Non-Final OA — Pending Sep 16, 2024
18819710 SYSTEM AND METHODS FOR AUTOMATED DEEP BRAIN STIMULATION PARAMETER SELECTION VIA META-ACTIVE LEARNING OF EVOKED POTENTIALS LUKJAN, SEBASTIAN X 3792 §101§102§103§112 Final Rejection — Pending Aug 29, 2024
18730610 Phosphate Membrane Nanodiscs Conjugated to Therapeutic Agents and Medical Uses Thereof BARRON, SEAN C 1653 §102§103 Non-Final OA — Pending Jul 19, 2024
18756360 Nucleoside Prodrugs and Uses Related Thereto STOCKTON, LAURA LYNNE 1626 §112DP Non-Final OA — Pending Jun 27, 2024
18742659 RNA-Dependent RNA Polymerase Inhibitory Compounds, Uses in Managing Viral Infections, and Pharmaceutical Compositions BANERJEE, KOYELI 1658 §103§112 Non-Final OA — Pending Jun 13, 2024
18680912 Methods of Producing Astrocytes or Promoting Astrocyte Development and Cell Culture Compositions Related Thereto GRABER, JAMES J 1631 §102§112 Non-Final OA — Pending May 31, 2024
18673818 Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto MOORE, SUSANNA 1624 §112Other Final Rejection — Pending May 24, 2024
18709256 Prodrugs of Neurosteroid Analogs and Uses Thereof JAVANMARD, SAHAR 1622 §112 Non-Final OA — Pending May 10, 2024
18702922 TREATMENT OF VIRUSES WITH ANTIVIRAL NUCLEOSIDES CHO, DAVID H 1693 §103§112DP Non-Final OA — Pending Apr 19, 2024
18698693 3D AUXETIC STRUCTURES AND FABRICATION METHODS THEREOF STEWART, ALVIN J 3799 §102 Non-Final OA — Pending Apr 04, 2024
18612453 SYSTEMS AND METHODS FOR DRIVING NEURAL ACTIVITY TO CONTROL BRAIN SIGNALING AND GENE EXPRESSION DORNA, CARRIE R 3791 §112DP Non-Final OA — Pending Mar 21, 2024
18291630 PHOSPHATE PRODRUGS OF CANNABINOIDS RAHMANI, NILOOFAR 1691 §102§112 Non-Final OA — Pending Jan 24, 2024
18580674 BAK ACTIVATORS, PHARMACEUTICAL COMPOSITIONS, AND USES IN TREATING CANCER HAVLIN, ROBERT H 1626 §102§103§112 Final Rejection — Pending Jan 19, 2024
18579142 T Cell Receptors (TCR) to Human Papillomavirus Proteins, Compositions, and Uses Thereof GODDARD, LAURA B 1642 §101§102§103§112 Non-Final OA — Pending Jan 12, 2024
18577171 CD8(+) Stem-Like Chronic Memory Cell Based Therapies and Compositions Related Thereto CHATTIN, AMY MARIE 1643 §103§112 Non-Final OA — Pending Jan 05, 2024
18527046 Catheter Retention Device STIMPERT, PHILIP EARL 3783 §102§103§112 Non-Final OA — Pending Dec 01, 2023
18561673 JAK Inhibitors for Managing Conditions in Patients with Down's Syndrome or Other Trisomy LANDSMAN, ROBERT S 1647 §112 Non-Final OA — Pending Nov 16, 2023
18510060 Methods of Treating Cancer and Infectious Diseases Using Cell Based Therapies SINGH, ANOOP KUMAR 1632 §103§112DP Non-Final OA — Pending Nov 15, 2023
18558874 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO GALSTER, SAMUEL LEONARD 1693 §103 Final Rejection — Pending Nov 03, 2023
18558026 CELL POTENCY ASSAYS, PLATFORMS, AND METHODS OF USE ARMATO JR, DENNIS IGNATIUS 1651 §102§112 Final Rejection 6d Pending Oct 30, 2023
18285778 NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS LEWIS, PATRICK T 1691 §103 Non-Final OA 2d overdue Pending Oct 05, 2023
18359435 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO LAU, JONATHAN S 1693 §103 Final Rejection — Pending Jul 26, 2023
18176021 CIRCULAR RNAS AND THEIR USE IN IMMUNOMODULATION LEONARD, ARTHUR S 1631 §103 Final Rejection — Pending Feb 28, 2023
18111350 RESPONSE-GUIDED HCV THERAPY CHANDRAKUMAR, NIZAL S 1625 §103§112 Non-Final OA — Pending Feb 17, 2023
18000865 DIRECT IN VIVO REPROGRAMMING USING TRANSCRIPTION FACTOR ETV2 GENE FOR ENDOTHELIAL CELL AND VESSEL FORMATION KIM, TAEYOON 1631 §102§103 Non-Final OA 49d overdue Pending Dec 06, 2022
17925179 COMPOSITIONS AND METHODS FOR DETECTING AND TREATING A SARS-COV-2 INFECTION SALVOZA, M FRANCO G 1672 §103§112 Non-Final OA — Pending Nov 14, 2022
17908766 Radionuclide Tracers of 1-Amino-3,4-Difluorocyclopentane-1-Carboxylic Acid, Derivatives, and Uses Thereof WESTERBERG, NISSA M 1618 §103 Non-Final OA 67d overdue Pending Sep 01, 2022
17842433 CSF-BASED PROGNOSTIC BIOMARKERS IN ALZHEIMER'S DISEASE AND METHODS OF USE THEREOF FRITCHMAN, REBECCA M 1758 §103 Final Rejection — Pending Jun 16, 2022
17435594 Botanical Extracts and Compounds from Castanea Plants and Methods of Use ISMAIL, REHANA 1625 §101§102§112 Final Rejection 30d overdue Pending Sep 01, 2021

Managing Emory University's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Emory University have?

Emory University has 33 pending office actions as of November 2026, spread across 24 art units and 33 examiners.

Which USPTO examiner handles the most Emory University applications?

Jonathan T Kuo has the most, with 1 of Emory University's pending office actions.

What technology area are Emory University's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month